Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

FGF23 concentrations measured using “intact” assays similar but not interchangeable

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21:1427–1435

  2. 2.

    Sinha MD, Turner C, Dalton RN, Rasmussen P, Waller S, Booth CJ, Goldsmith DJ (2012) Investigating FGF23 levels and its relationship with declining renal function in paediatric patients with pre-dialysis CKD stage 3–5. Nephrol Dial Transplant. doi:10.1093/ndt/gfs109

  3. 3.

    Wesseling-Perry K (2011) FGF23: is it ready for prime time? Clin Chem 57(11):1476–1477

  4. 4.

    Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shake JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055–2061

  5. 5.

    Ito N, Fukumoto S, Takeuchi Y, Yasuda T, Hasegawa Y, Takemoto F, Tajima T, Dobashi K, Yamazaki Y, Yamashita T, Fujita T (2005) Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 23(6):435–440

  6. 6.

    Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJA (2012) PTH—a particularly tricky hormone: why measure it at all in kidney patients? CJASN. doi:10.2215/CJN.09580911

  7. 7.

    Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int 76(Suppl 113):S1–S130

  8. 8.

    Binkley N, Krueger D, Gemar D, Drezner MK (2008) Correlation among 25-hydroxyvitamin D assays. J Clin Endocrinol Metab 93:1804–1808

Download references

Acknowledgments

The research was funded/supported by the National Institute for Health Research (NIHR), Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Conflict of interest

None.

Author information

Correspondence to Manish D. Sinha.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sinha, M.D., Turner, C. & Goldsmith, D.J. FGF23 concentrations measured using “intact” assays similar but not interchangeable. Int Urol Nephrol 45, 1821–1823 (2013). https://doi.org/10.1007/s11255-013-0451-x

Download citation

Keywords

  • Chronic Kidney Disease
  • FGF23 Level
  • Interassay Coefficient
  • Adverse Cardiovascular Outcome
  • FGF23 Concentration